Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis
Jund R, et al
Published in Acta Oto-Laryngologica
Methodology
Pooled efficacy analysis of two randomised, placebo-controlled trials with safety assessed per individual trial; oral 3 x 160 mg BNO 1016 or placebo for 15 days across five site visits; symptoms scored per EPOS 2012 with ultrasonography to confirm diagnosis and remission, plus SNOT-20 GAV quality of life.
Key Findings
Pooled efficacy data from two similar randomised placebo-controlled trials covered 589 patients with acute viral rhinosinusitis taking 3 x 160 mg of the herbal preparation BNO 1016 (n = 294) or placebo (n = 295) for 15 days. The major symptom score fell by a mean of 10.02 points to 2.47 with BNO 1016 versus 9.87 to 3.63 with placebo, a between-group difference of 1.16 points at end of therapy (p < 0.0001). Patient-reported quality of life on the SNOT-20 GAV also favoured the herbal treatment (p = 0.0015).
Conclusions
Daily intake of 480 mg BNO 1016 for 15 days is an effective treatment in acute viral rhinosinusitis.
Limitations
A pooled analysis of two manufacturer-run trials rather than a prospectively planned meta-analysis; the 1.16-point symptom difference is small relative to the roughly 10-point improvement seen in both arms, and follow-up stopped at 15 days.
Supplements Studied
The gentian-containing herbal combination BNO 1016 reduced major symptom scores significantly faster than placebo in acute viral rhinosinusitis.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.